IR Medtek LLC was founded in 2019 in collaboration with the Ohio State Innovation Fund and four co-founders. The company exclusively licensed the groundbreaking technology developed at The Ohio State University and the James Cancer Hospital. The technology can not only be used for the early, non-evasive detection of skin and other cancers, but also intraoperatively for margin detection as well as a variety of other potential applications including non-cancerous detection.
Two clinical studies have been completed to date validating the technology. IR Medtek is currently conducting two more studies to further advance the technology. Our initial goal is to commercialize the technology into various medical devices.
The company’s mission is to improve healthcare outcomes through adoption of the technology. We intend to provide medical professionals with more information such that they may provide better and more timely care.